Episode 179 - April 10, 2026

What It Covers

Biotech Hangout Episode 179 covers biotech market performance with XBI up 84% year-over-year, Merck's $6.7B Terns acquisition backstory, Gilead's $3.15B Tubulus ADC platform deal, Neurocrine's $3B Soleno purchase, FDA regulatory developments, and new obesity drug approvals from Novo Nordisk and Eli Lilly.

Key Questions Answered

• •Biotech Market Outperformance: The XBI ETF hit a 52-week high near 132, delivering an 84% return over the past year versus 30% for the S&P 500 and 39% for the Nasdaq. Investors who entered biotech at the Liberation Day low of 71 more than doubled their money, making the sector the strongest-performing major equity category over that period.
• •M&A Data Room Risk: The Terns-Merck SEC filing reveals that acquirers accessing confidential data rooms can materially reprice deals downward. Party C dropped its $61 bid entirely after seeing updated Cardinal study data showing degraded MMR rates; Merck lowered its offer from $61 to $50 before settling at $53. Investors should monitor SEC filings post-announcement for deal process disclosures.
• •Platform vs. Asset Acquisitions: Gilead's $3.15B Tubulus deal, following a $20M partnership signed in December 2024, illustrates a strategy of using small licensing deals as due diligence before full platform acquisitions. This approach gave Gilead confidence in Tubulus's differentiated ADC methodology before committing capital, offering a replicable framework for evaluating biotech platform investments.
• •Mid-Cap Buyers Expanding M&A Competition: Neurocrine, Servier, and BioMarin demonstrate that mid-sized pharma companies are now active acquirers alongside large caps, increasing competitive bidding. Neurocrine's Soleno acquisition at roughly $3B adds Vykat XR, annualizing above $400M with blockbuster potential, while reducing dependence on its higher-risk late-stage neurology pipeline and maintaining cash flows within the XBI.
• •GLP-1 Genetic Response Variability: A Nature paper using 23andMe data from approximately 25,600 subjects identified a missense variant in the GLP-1 receptor associated with nearly one additional kilogram of weight loss per gene copy and altered side effect profiles. Comparing efficacy across GLP-1 trials without accounting for patient genetic composition produces misleading conclusions about drug performance.